Dr. Freedland is Principal at Samsara Biocapital, which he joined in 2017. Prior to Samsara, Dr. Freedland was a Principal at Sofinnova Ventures, where he focused on biopharmaceutical investments. He played a central role in Sofinnova’s investments in Civitas (acquired by Acorda), NextCure, NuCana Biomed (NCNA), Principia Biopharma, Spark Therapeutics (acquired by Roche), Ziarco (acquired by Novartis) and ZS Pharma (acquired by AstraZeneca). Prior to Sofinnova, Dr. Freedland was a Principal at Novo A/S. Before his transition to healthcare investing, he was a Vice President in the healthcare investment banking practice at Morgan Stanley, where he advised on over $12 billion of strategic and financing transactions in the biopharmaceutical and life science tools/diagnostics sectors. Prior to transitioning to life science finance, he worked as a Research Scientist for Roche, focusing on preclinical drug discovery and novel target identification for psychiatric and neurodegenerative diseases. He received his PhD in Pharmacology from Wake Forest University School of Medicine and his MBA from the Kellogg School of Management. He holds a BA in Psychology and Religious Studies from Connecticut College.